Genmab AS

Genmab AS R&D per Employee

The R&D Spending per Employee of Genmab AS (GMAB) as of Nov 22, 2026 is 515,097.23 USD. In the previous year, R&D Spending per Employee was 3.22 M USD — a change of -83.99% (lower).

R&D per Employee

515,097.23USD

YoY

-83.99%

Last updated:

R&D Spending per Employee of Genmab AS is 2025 515,097.23 USD. R&D Spending per Employee of Genmab AS was 2024 3.22 M USD. It decreases by -83.99% lower compared to the previous year.

The Genmab AS R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
472,485.64 USD
Jan 1, 2019
787,718.72 USD
Jan 1, 2020
1.04 M USD
Jan 1, 2021
1.38 M USD
Jan 1, 2022
1.84 M USD
Jan 1, 2023
2.52 M USD
Jan 1, 2024
3.22 M USD
Jan 1, 2025
515,097.23 USD
The Genmab AS R&D per Employee history
YEARR&D per EmployeeYoY
515,097.23USD-83.99%
3.22 MUSD+27.76%
2.52 MUSD+37.18%
1.84 MUSD+33.03%
1.38 MUSD+33.28%
1.04 MUSD+31.48%
787,718.72USD+66.72%
472,485.64USD+63.70%
288,635.85USD+32.29%
218,182.90USD+35.52%
160,995.71USD-3.56%
166,945.86USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

R&D Spending per Employee of Genmab AS is 515,097.23 USD in 2025.

R&D Spending per Employee of Genmab AS changed from 3.22 M USD to 515,097.23 USD, representing a -83.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Genmab AS since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Genmab AS

All Key Metrics — Genmab AS